Abbott heart drug shows scant benefit-study (Reuters)


Reuters - Abbott Laboratories Inc.'s experimental
heart failure drug Simdax failed to significantly improve
survival over the current standard treatment for the sickest
patients after 180 days, according to a new study presented on
Wednesday.